Home » Newsletters » BioWorld Science

BioWorld Science

May 12, 1997

View Archived Issues

Glaxo obtains license to technology and porphyrin compound for dermatological diseases

D-21266 demonstrates advantages over miltefosine in vivo

Positive preclinical results with CB-1267 in combination with 9-cis-RA for prostate cancer

In vivo efficacy and pharmacokinetic profile of XR-9051

TAS-103 shows antitumor activity against orthotopically implanted human cancers

Serine protease inhibitors described by 3-D

Modified p53 constructs prepared by the Wistar Institute

Antineoplastic/immunostimulating glycan discovered by U. of Illinois researchers

Prodrugs of calcitriol disclosed by Wisconsin Alumni Research Foundation

Selective beta3-agonists from Lilly

ET antagonists described by Ciba-Geigy Japan (Novartis)

ImmuLogic receives funds from NIH to develop cocaine vaccine

Schering-Plough evaluates novel farnesyltransferase inhibitor

RPR selects farnesyltransferase inhibitor for in vivo evaluation

Taiho discovers potent and selective cdc25PTP inhibitors

Parke-Davis develops new c-src TK inhibitors

Glycan-conjugated 5-FU for the treatment of hepatocellular cancer/metastases

Sequana and Boehringer Ingelheim expand alliance for asthma research

Retinoid-like compounds that induce apoptosis in cancer cells

Procter & Gamble and Hoechst Marion Roussel to comarket Actonel

Sonus and Valois collaborate on development of aerosol drug delivery system

Lilly prepares raloxifene analogs that reverse MRP-mediated resistance

Penederm receives approval for butenafine in Canada

Dual 5alpha-reductase type I/II inhibitor from Lilly for prostatic cancer

Alpha-Beta Technology acquires MycoTox and expands antifungal program

BioSpecifics receives grant to develop collagenase injection for Dupuytren's disease

Procept's topical microbicide shown to be contraceptive

Effects of L-692429 in obese and nonobese young men

Osaterone enhances bone formation in ovariectomized rats

Update on HemispheRx Biopharma's Ampligen

Hepatoprotective effects of ET antagonist TAK-044

Ono-4007 restores immune responses in tumor-bearing animals